Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024)
Inhibikase Therapeutics (IKT) has disclosed Return on Sales for 5 consecutive years, with 20063937.0% as the latest value for Q3 2024.
- Quarterly Return on Sales fell 2006387707.0% to 20063937.0% in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 20063937.0% through Sep 2024, down 2006387522.0% year-over-year, with the annual reading at 77.12% for FY2023, 6974.0% up from the prior year.
- Return on Sales for Q3 2024 was 20063937.0% at Inhibikase Therapeutics, down from 238.85% in the prior quarter.
- The five-year high for Return on Sales was 1.87% in Q1 2021, with the low at 20063937.0% in Q3 2024.
- Average Return on Sales over 5 years is 1288008.65%, with a median of 68.2% recorded in 2022.
- The sharpest move saw Return on Sales soared 252523bps in 2022, then plummeted 2000000000bps in 2024.
- Over 5 years, Return on Sales stood at 7.09% in 2020, then plummeted by -36487bps to 2593.43% in 2021, then soared by 97bps to 68.2% in 2022, then crashed by -6457080bps to 4403566.0% in 2023, then plummeted by -356bps to 20063937.0% in 2024.
- According to Business Quant data, Return on Sales over the past three periods came in at 20063937.0%, 238.85%, and 102.85% for Q3 2024, Q2 2024, and Q1 2024 respectively.